Patient and public involvement in the design and protocol development for a platform randomised trial to evaluate diagnostic tests to optimise antimicrobial therapy (PROTECT).

NIHR open research Pub Date : 2024-09-20 eCollection Date: 2024-01-01 DOI:10.3310/nihropenres.13591.1
Martina Svobodova, Liza Keating, Melanie Gager, Cherry-Ann Waldron, Sammy Ainsworth, Julie Carman, Sarah Jones, Margaret Ogden, Graham Prestwich
{"title":"Patient and public involvement in the design and protocol development for a platform randomised trial to evaluate diagnostic tests to optimise antimicrobial therapy (PROTECT).","authors":"Martina Svobodova, Liza Keating, Melanie Gager, Cherry-Ann Waldron, Sammy Ainsworth, Julie Carman, Sarah Jones, Margaret Ogden, Graham Prestwich","doi":"10.3310/nihropenres.13591.1","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Our patient and public involvement activities were part of a project aiming to develop a master protocol and National Institute for Health and Care research application for the PROTECT trial aiming to assess the effectiveness, implementation, and efficiency of antimicrobial stewardship interventions, to safely reduce unnecessary antibiotic usage by excluding severe bacterial infection in acutely unwell patients.</p><p><strong>Methods: </strong>Three public involvement sessions were held with representation from young people and parents, people from diverse backgrounds and people with experience of presenting to the emergency department with undifferentiated illness. The teleconference meetings lasted between 60-90 minutes, were recorded, notes were subsequently taken, and findings summarised. The data was collected on September 13, 2023, October 14, 2023 and February 28, 2024.</p><p><strong>Results: </strong>Working with public involvement contributors and public involvement groups at the protocol development stage provided an opportunity for the public to shape and influence the trial. We were able to establish the feasibility of the trial in the proposed setting and gain insights into how it would be perceived by potential trial participants. Antibiotic resistance was viewed as an urgent problem and research evaluating new technologies was deemed timely and important. The platform design was considered appropriate, time and cost-effective. Deferred and electronic methods of consent were viewed as acceptable if a clear and inclusive explanation is provided.</p><p><strong>Conclusions: </strong>Having access to public contributors with relevant lived experience was an important resource for the trial team. Identification and recruitment of public contributors via working with existing public involvement groups across the UK enabled the trial team to involve public members with varied life experiences and from diverse backgrounds. This project was a good practice example of how public involvement groups and practitioners across the UK can work together to deliver public involvement that is inclusive of relevant groups.</p>","PeriodicalId":74312,"journal":{"name":"NIHR open research","volume":"4 ","pages":"52"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11736108/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"NIHR open research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3310/nihropenres.13591.1","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Our patient and public involvement activities were part of a project aiming to develop a master protocol and National Institute for Health and Care research application for the PROTECT trial aiming to assess the effectiveness, implementation, and efficiency of antimicrobial stewardship interventions, to safely reduce unnecessary antibiotic usage by excluding severe bacterial infection in acutely unwell patients.

Methods: Three public involvement sessions were held with representation from young people and parents, people from diverse backgrounds and people with experience of presenting to the emergency department with undifferentiated illness. The teleconference meetings lasted between 60-90 minutes, were recorded, notes were subsequently taken, and findings summarised. The data was collected on September 13, 2023, October 14, 2023 and February 28, 2024.

Results: Working with public involvement contributors and public involvement groups at the protocol development stage provided an opportunity for the public to shape and influence the trial. We were able to establish the feasibility of the trial in the proposed setting and gain insights into how it would be perceived by potential trial participants. Antibiotic resistance was viewed as an urgent problem and research evaluating new technologies was deemed timely and important. The platform design was considered appropriate, time and cost-effective. Deferred and electronic methods of consent were viewed as acceptable if a clear and inclusive explanation is provided.

Conclusions: Having access to public contributors with relevant lived experience was an important resource for the trial team. Identification and recruitment of public contributors via working with existing public involvement groups across the UK enabled the trial team to involve public members with varied life experiences and from diverse backgrounds. This project was a good practice example of how public involvement groups and practitioners across the UK can work together to deliver public involvement that is inclusive of relevant groups.

患者和公众参与平台随机试验的设计和方案制定,以评估诊断测试以优化抗菌治疗(PROTECT)。
背景:我们的患者和公众参与活动是一个项目的一部分,该项目旨在制定一个总体方案和国家卫生与保健研究所的PROTECT试验研究申请,旨在评估抗菌药物管理干预措施的有效性、实施和效率,通过排除急性不适患者的严重细菌感染,安全地减少不必要的抗生素使用。方法:举办了三次公众参与会议,代表来自年轻人和家长,来自不同背景的人,以及有未分化疾病急诊就诊经验的人。电话会议持续60-90分钟,进行录音,随后作笔记,并总结调查结果。数据分别于2023年9月13日、2023年10月14日和2024年2月28日收集。结果:在方案制定阶段与公众参与贡献者和公众参与团体合作,为公众塑造和影响试验提供了机会。我们能够在提议的环境中建立试验的可行性,并深入了解潜在试验参与者对试验的看法。抗生素耐药性被视为一个紧迫的问题,研究评估新技术被认为是及时和重要的。该平台的设计被认为是合适的,符合时间和成本效益。如果提供了明确和包容性的解释,则认为延迟和电子同意方法是可以接受的。结论:获得具有相关生活经验的公共贡献者是试验团队的重要资源。通过与英国各地现有的公众参与团体合作,确定和招募公众贡献者,使试验团队能够吸收具有不同生活经历和不同背景的公众成员。这个项目是一个很好的实践例子,说明英国各地的公众参与团体和从业人员如何共同努力,实现包括相关团体在内的公众参与。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信